FIBLAST TRAFERMIN IN TREATMENT OF INTERMITTENT CLAUDICATION

FIBLAST TRAFERMIN 治疗间歇性跛行

• 批准号: 6281687
• 负责人: SAMUEL WARD CASSCELLS
• 金额: $ 1.36万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6281687
• 关键词: body movement; cardiovascular disorder chemotherapy; claudication; clinical research; exercise; fibroblast growth factor; functional ability; human subject; human therapy evaluation; ischemia; limbs

Patients with intermittent claudication experience muscle aching or cramping during activity secondary to ischemia. The aim of this study is to determine if basic Fibroblast Growth Factor is effective in safely treating these patients. It will determine whether bFGF can increase blood flow in a sustained fashion due to an increase in vascular supply via new capillary formation and increased collateral flow. Parameters to be tested include exercise performance, functional status, improvement of hyperemic calf flow, and lower limb blood flow.

间歇性跛行的患者会出现肌肉酸痛或 活动期间继发于缺血的痉挛。 本研究的目的是 确定碱性成纤维细胞生长因子是否有效安全 治疗这些患者。 它将决定bFGF是否可以增加 由于血管供应增加，血流持续流动 通过新的毛细血管形成和增加的侧支血流。 参数为 测试内容包括运动表现、功能状态、改善情况 充血的小腿血流和下肢血流。